Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer

Carcinoma, Renal Cell Clinical Trial

Official title:

Phase II Study of Interleukin- 2 and Bevacizumab in Patients With Progressive Metastatic Renal Cell Carcinoma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00440973
• Other study ID #: PAC IRB #03-0194-05
• Secondary ID: 16117
• Status: Terminated
• Phase: Phase 2
• First received: February 23, 2007
• Last updated: March 15, 2016
• Start date: October 2006
• Est. completion date: November 2007

Study information

• Verified date: March 2016
• Source: The Methodist Hospital System
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if the combination of therapy to strengthen the immune system (Interleukin - 2) plus a specific tumor target therapy (Bevacizumab) can prolong the time between the start of treatment and disease progression, decrease tumor size, as well as determine if the combination therapy is safer and less toxic than the standard treatment for renal cell carcinoma.

Description:

The standard first-line treatment for patients with metastatic RCC is IL-2 at higher doses, but associated with higher frequency of toxicities. IL-2 given at lower doses have demonstrated similar results than higher doses but it requires further study. RCC is highly vascular and expresses high levels of VEGF. Bevacizumab is a monoclonal antibody directed against the Vascular Endothelial Growth Factor (VEGF) responsible for angiogenesis.

The study is designed to evaluate a response defined as time to progression, safety and toxicity in patients with metastatic renal cell carcinoma. Tissue correlation to evaluate the impact of vascular VEGF on clinical outcome will be retrospectively performed

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 6
• Est. completion date: November 2007
• Est. primary completion date: October 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Pathological proof of clear cell carcinoma (or mixed tumors = 75% clear cell component)

• Evidence of measurable metastatic disease, no progression diseases or the patient's condition will not need radiotherapy in the next 4 weeks.

• Previous definitive radiotherapy to 1 metastatic site is acceptable

• At least 4 weeks have elapsed since radiation therapy

• Patients must be free of serious co-morbidity and have a life expectancy of =24 weeks

• Patients should have adequate physiologic reserves as evidence of adequate performance status, blood parameters, hepatic and kidney function, no evidence of active cardiac diseases and showing an acceptable function and adequate coagulation profile.

Exclusion Criteria:

• History of central nervous System metastases

• Known HIV positive

• Recent history of brain's vascular disease within 6 months; patients requiring regular antianginal therapy (coronary disease) or insufficient circulation in lower extremities are not eligible

• Active autoimmune disease

• Patients who have had steroid therapy in the past three weeks

• Patients taking concurrent anticancer drugs

• Biphosphonates (Zometa) are not allowed, unless started 4 weeks prior to participation in the study

• Female patients pregnant or breast-feeding

• The patient has an unstable medical condition, such as uncontrolled Diabetes mellitus or Hypertension; active infections requiring systemic antibiotics, antivirals, or antifungal; clinical evidence of cardiac or pulmonary dysfunction including, uncontrolled arrhythmias, unstable coagulation disorders; or recent myocardial infarction (within 6 months)

• Any condition including abnormal laboratory results, that in the opinion of the investigator places the patient at an unacceptable risk if he/she participate in the study

• Prior malignancy (within the last 3 years), except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer or other cancer for which the patient has been - free for at least 3 years

• Uncontrolled Blood pressure > 150/100

• Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, anticipation of need for major surgical procedure during the course of the study

• Minor surgery 7 days before day 0

• Serious, non healing wound, ulcer, or bone fracture; and,inability to accomplish the treatment

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma, Renal Cell

Intervention

Drug:
• Bevacizumab
monoclonal antibody with anti-angiogenesis properties used as chemotherapy
• Interleukin-2
immunotherapy - cytokine signaling molecule used as an immune system regulator to trigger T & B lymphocyte proliferation

Locations

Country	Name	City	State
United States	Baylor College of Medicine - Methodist Hospital	Houston	Texas

Sponsors (2)

Lead Sponsor	Collaborator
The Methodist Hospital System	Genentech, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	time to progression	currently data no longer available	During study (currently data no longer available)	No
Secondary	Collect data on tumor responses produced by interleukin-2 and Bevacizumab	currently data no longer available	During study (currently data no longer available)	No
Secondary	Evaluate safety and toxicity of the combination of interleukin-2 and Bevacizumab for patients with progressive metastatic renal cell carcinoma.	currently data no longer available	During study (currently data no longer available)	No